Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer. Its products pipeline also comprises BION-1301, a B-select monoclonal antibody novel therapy for multiple myeloma; A PRoliferation-Inducing Ligand for the treatment of multiple myeloma, chronic lymphocytic leukemia, and colorectal carcinoma; CD27, a co-stimulatory receptor for the treatment of cancer; and CTLA-4 for the treatment of advanced melanoma and other cancers. The company's pLADD program is based on proprietary attenuated strains of Listeria that have been engineered to express tumor neo antigens that are specific to an individual patient's tumor. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Janssen Biotech, Inc, and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADRO
Previous Symbol
CUSIPN/A
Phone510-848-4400
Debt
Debt-to-Equity RatioN/A
Current Ratio9.32
Quick Ratio9.32
Price-To-Earnings
Trailing P/E Ratio-1.96
Forward P/E Ratio-2.36
P/E GrowthN/A
Sales & Book Value
Annual Sales$17.24 million
Price / Sales12.85
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.07 per share
Price / Book0.91
Profitability
EPS (Most Recent Fiscal Year)($1.42)
Net Income$-91,860,000.00
Net Margins-591.66%
Return on Equity-50.03%
Return on Assets-23.51%
Miscellaneous
Employees162
Outstanding Shares79,400,000
Market Cap$212.80 million
OptionableOptionable
Aduro BioTech (NASDAQ:ADRO) Frequently Asked Questions
What is Aduro BioTech's stock symbol?
Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO."
How were Aduro BioTech's earnings last quarter?
Aduro BioTech Inc (NASDAQ:ADRO) issued its earnings results on Tuesday, October, 30th. The biotechnology company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.02. The biotechnology company had revenue of $3.06 million for the quarter, compared to the consensus estimate of $4.59 million. Aduro BioTech had a negative net margin of 591.66% and a negative return on equity of 50.03%. View Aduro BioTech's Earnings History.
When is Aduro BioTech's next earnings date?
What price target have analysts set for ADRO?
7 brokers have issued twelve-month price targets for Aduro BioTech's shares. Their predictions range from $6.00 to $15.00. On average, they anticipate Aduro BioTech's stock price to reach $9.80 in the next year. This suggests a possible upside of 249.7% from the stock's current price. View Analyst Price Targets for Aduro BioTech.
What is the consensus analysts' recommendation for Aduro BioTech?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aduro BioTech in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aduro BioTech.
What are Wall Street analysts saying about Aduro BioTech stock?
Here are some recent quotes from research analysts about Aduro BioTech stock:
- 1. According to Zacks Investment Research, "Aduro's three distinct technology platforms are being utilized by several companies to develop treatments for several cancer indications. The company’s collaboration agreements with large pharma companies — Novartis and Johnson & Johnson — not only validate its research platforms but also enhance its financial position, providing it with adequate funds. However, with no approved products in Aduro’s portfolio, the company heavily depends on funds generated from collaboration and license agreements, government grants as well as other payments for the development of its pipeline candidates. Thus, an inability to secure sufficient funding could hinder Aduro’s pipeline progress. Shares of the company have underperformed the industry so far this year." (12/6/2018)
- 2. Cantor Fitzgerald analysts commented, "ADRO shares are trading up modestly on the disclosure of a $3 million milestone from MRK’s (Merck, NC) initiation of a Phase I trial with the anti- CD27 candidate." (3/5/2018)
- 3. HC Wainwright analysts commented, "All Three Platforms Now Clinical Stage; We Have High Expectations for B-Select Platform B-select investment starts bearing clinical stage candidates. Aduro announced the expected initiation of a Phase 1/2 clinical trial with its anti-APRIL antibody, BION-1301. This two part, open-label study, is being conducted in relapsed or refractory multiple myeloma patients (at least three prior systemic therapies). Once the recommended Phase 2 dose is identified in part 1, patients are to be expanded at the selected dose with the primary endpoint of overall response rate. The APRIL/BCMA pathway was also a hot topic at the recent ASH conference as an encouraging new target against myeloma. A proliferation inducing ligand (APRIL) is one of the main high affinity ligands that binds and activates BCMA resulting in a pro-survival cell signal. APRIL is a member of the TNF family and is overexpressed in patients with multiple myeloma (MM)." (12/13/2017)
Has Aduro BioTech been receiving favorable news coverage?
News stories about ADRO stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aduro BioTech earned a coverage optimism score of 1.5 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near future.
Who are some of Aduro BioTech's key competitors?
Some companies that are related to Aduro BioTech include Intra-Cellular Therapies (ITCI), Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Crinetics Pharmaceuticals (CRNX), Dicerna Pharmaceuticals (DRNA), ImmunoGen (IMGN), Y-mAbs Therapeutics (YMAB), Lexicon Pharmaceuticals (LXRX), AC Immune (ACIU), Principia Biopharma (PRNB), Radius Health (RDUS), Aptinyx (APTX), Inflarx (IFRX), ProQR Therapeutics (PRQR) and MacroGenics (MGNX).
Who are Aduro BioTech's key executives?
Aduro BioTech's management team includes the folowing people:
- Mr. Stephen T. Isaacs, Chairman, CEO & Pres (Age 69)
- Dr. Andrea van Elsas, Chief Scientific Officer (Age 51)
- Mr. Blaine E. Templeman, Corp. Devel. Head, Chief Legal Officer and Sec. (Age 52)
- Ms. Jennifer Lew, Chief Financial Officer (Age 45)
- Ms. Alexandra Santos, Exec. Director of Corp. Affairs & Investor Relations
When did Aduro BioTech IPO?
(ADRO) raised $119 million in an IPO on Wednesday, April 15th 2015. The company issued 7,000,000 shares at a price of $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.
Who are Aduro BioTech's major shareholders?
Aduro BioTech's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.45%), Vanguard Group Inc. (5.07%), Baillie Gifford & Co. (3.88%), Aquilo Capital Management LLC (2.65%), FMR LLC (2.50%) and Vident Investment Advisory LLC (0.38%). Company insiders that own Aduro BioTech stock include Blaine Templeman, Dirk G Brockstedt, Elsas Andrea Van, Gregory W Schafer, Jennifer Lew, Natalie Sacks, Stephen T Isaacs and Thomas W Dubensky. View Institutional Ownership Trends for Aduro BioTech.
Which major investors are selling Aduro BioTech stock?
ADRO stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Oracle Investment Management Inc., TIAA CREF Investment Management LLC, Sofinnova Ventures Inc, Virtus ETF Advisers LLC and Vident Investment Advisory LLC. Company insiders that have sold Aduro BioTech company stock in the last year include Blaine Templeman, Dirk G Brockstedt, Elsas Andrea Van, Gregory W Schafer, Jennifer Lew, Natalie Sacks and Stephen T Isaacs. View Insider Buying and Selling for Aduro BioTech.
Which major investors are buying Aduro BioTech stock?
ADRO stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Baillie Gifford & Co., Dimensional Fund Advisors LP, Hsbc Holdings PLC, Aquilo Capital Management LLC, Panagora Asset Management Inc. and Jefferies Group LLC. View Insider Buying and Selling for Aduro BioTech.
How do I buy shares of Aduro BioTech?
Shares of ADRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aduro BioTech's stock price today?
One share of ADRO stock can currently be purchased for approximately $2.8027.
How big of a company is Aduro BioTech?
Aduro BioTech has a market capitalization of $212.80 million and generates $17.24 million in revenue each year. The biotechnology company earns $-91,860,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. Aduro BioTech employs 162 workers across the globe.
What is Aduro BioTech's official website?
How can I contact Aduro BioTech?
Aduro BioTech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-848-4400 or via email at [email protected]
MarketBeat Community Rating for Aduro BioTech (NASDAQ ADRO)
MarketBeat's community ratings are surveys of what our community members think about Aduro BioTech and other stocks. Vote "Outperform" if you believe ADRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
